GTS Securities’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$208K Buy
+894
New +$207K ﹤0.01% 1525
2026
Q1
– Sell
-1,270
Closed -$220K – 1558
2025
Q4
$220K Buy
1,270
+97
+8% +$17.7K 0.01% 1232
2025
Q3
$224K Buy
+1,173
New +$208K 0.01% 1223
2025
Q2
– Sell
-1,481
Closed -$251K – 1311
2025
Q1
$251K Buy
+1,481
New +$243K 0.01% 1043
2024
Q4
– Sell
-2,842
Closed -$441K – 1968
2024
Q3
$441K Buy
+2,842
New +$424K ﹤0.01% 2940
2024
Q2
– Sell
-5,827
Closed -$798K – 4007
2024
Q1
$776K Buy
5,827
+3,525
+153% +$457K ﹤0.01% 2186
2023
Q4
$317K Buy
+2,302
New +$303K ﹤0.01% 3158

Other funds holding DGX

GTS Securities's DGX Position: Q3 2026 in Review

GTS Securities opened a new position in Quest Diagnostics (DGX) in Q3 2026: 894 shares worth $208K. The stake represents ﹤0.01% of the portfolio and ranks #1525 among its holdings. This is a return to the name: GTS Securities previously reported a position in DGX as recently as Q4 2025.

GTS Securities first reported a position in DGX in Q4 2023 and has held it in 7 quarters since. The position peaked at $776K in Q1 2024. 1,126 funds tracked by Wall St. Rank hold DGX as of Q3 2026.

  • GTS Securities held 894 shares of Quest Diagnostics worth $208K as of Q3 2026.
  • Quest Diagnostics was a new GTS Securities position in Q3 2026.
  • Quest Diagnostics made up ﹤0.01% of GTS Securities's portfolio in Q3 2026, its #1525 holding.
  • GTS Securities first reported a position in Quest Diagnostics in Q4 2023 and has held it in 7 quarters since.
  • GTS Securities's Quest Diagnostics position peaked at $776K in Q1 2024.
  • 1,126 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2026.

Based on GTS Securities's 13F filing for Q3 2026, filed 16 Nov 2026.